AstraZeneca beats Q2 earnings forecasts despite slight revenue miss, driven by oncology and rare diseases growth.
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
